CRISPR/Cas9 Genome-Editing Technology and Potential Clinical Application in Gastric Cancer.
Renata Sanches AlmeidaFernanda WisnieskiBruno Takao Real KariaMarilia de Arruda Cardoso SmithPublished in: Genes (2022)
Gastric cancer is the subject of clinical and basic studies due to its high incidence and mortality rates worldwide. Due to the diagnosis occurring in advanced stages and the classic treatment methodologies such as gastrectomy and chemotherapy, they are extremely aggressive and limit the quality of life of these patients. CRISPR/Cas9 is a tool that allows gene editing and has been used to explore the functions of genes related to gastric cancer, in addition to being used in the treatment of this neoplasm, greatly increasing our understanding of cancer genomics. In this mini-review, we seek the current status of the CRISPR/Cas9 gene-editing technology in gastric cancer research and clinical research.
Keyphrases
- crispr cas
- genome editing
- end stage renal disease
- current status
- newly diagnosed
- chronic kidney disease
- risk factors
- ejection fraction
- cardiovascular disease
- genome wide
- gene expression
- cardiovascular events
- young adults
- type diabetes
- prognostic factors
- single cell
- coronary artery disease
- combination therapy
- dna methylation
- transcription factor
- risk assessment
- locally advanced
- case control